Literature DB >> 581272

Encephalomyelopathy following intrathecal methotrexate treatment in a child with acute leukemia.

K Skullerud, K Halvorsen.   

Abstract

A previously undescribed type of encephalomyelopathy after prophylactic intrathecal methotrexate (MTX) treatment for acute leukemia is reported. The patient was treated systemically with vincristine, MTX, stereoids and mercaptopurine. Radiation therapy was not given. The neurologic symptoms started 24 hours after the completion of the fifth intrathecal MTX instillation and death ensued 18 days later. The lesions consisted of superficial and sharply circumscribed areas of incomplete necrosis with astrocytosis on the base of the brain and along the insula regions, around the foramina of Luschka, and over the superior and inferior colliculi. Similar superficial lesions were found over the surface of the cerebellum and along most of the surface of the spinal cord. Most of the affected areas in the brain were located under the large subarachnoid cisterns. In the cord the lesions were most pronounced along the entrance zones of the roots. There was also a severe loss of anterior horn cells. There were no signs of meningeal leukemia, no pathological changes were caused by the intrathecal MTX treatment.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 581272     DOI: 10.1002/1097-0142(197809)42:3<1211::aid-cncr2820420326>3.0.co;2-x

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

1.  Myelopathy following intrathecal chemotherapy in adults: a single institution experience.

Authors:  David Cachia; Carlos Kamiya-Matsuoka; Chelsea C Pinnix; Linda Chi; Hagop M Kantarjian; Jorge E Cortes; Naval Daver; Karin Woodman
Journal:  J Neurooncol       Date:  2015-02-10       Impact factor: 4.130

Review 2.  Atypical MRI findings in treatment-related leukoencephalopathy: case report.

Authors:  Y Ohmoto; K Kajiwara; S Kato; T Nisizaki; H Ito; S Tamura
Journal:  Neuroradiology       Date:  1996-02       Impact factor: 2.804

3.  Subacute leukoencephalopathy complicating acute lymphoblastic leukemia.

Authors:  F M Filloux; J J Townsend
Journal:  West J Med       Date:  1987-02

4.  Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients.

Authors:  N Guha-Thakurta; D Damek; C Pollack; F H Hochberg
Journal:  J Neurooncol       Date:  1999-07       Impact factor: 4.130

5.  Cerebral arterial disturbances in a transient encephalopathy induced by methotrexate.

Authors:  J Y Follezou; L Chauveinc; J M Guerin
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

6.  Cerebellar sclerosis in pediatric cancer patients.

Authors:  M Wizniter; R J Packer; L B Rorke; A T Meadows
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

7.  Experimental study on subacute neurotoxicity of methotrexate in cats.

Authors:  M Shibutani; R Okeda
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

8.  Vascular changes of methotrexate-related disseminated necrotizing leukoencephalopathy.

Authors:  K Suzuki; T Takemura; R Okeda; S Hatakeyama
Journal:  Acta Neuropathol       Date:  1984       Impact factor: 17.088

9.  Acute fever and delayed leukoencephalopathy following low dose intraventricular methotrexate.

Authors:  W Boogerd; J J vd Sande; D Moffie
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-10       Impact factor: 10.154

10.  Irreversible paraplegia following one time prophylactic intrathecal chemotherapy in an adult patient with acute lymphoblastic leukemia.

Authors:  Hea Yong Lee; Sung-il Im; Myoung-Hee Kang; Kwang Min Kim; Seok Hyun Kim; Hun-Gu Kim; Jung Hun Kang; Gyeong-Won Lee
Journal:  Yonsei Med J       Date:  2008-02-29       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.